Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Food Effect on the Safety and Pharmacokinetics of AD-230 in Healthy Adult Volunteers
NCT07618845Phase 1Not yet recruiting
- Sponsor
- Addpharma, Inc.
- Start
- May 2026
- Primary completion
- Jul 2026
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of telmisartan + amlodipine + chlorthalidone in chronic liver disease (CLD) (2 arms), sponsored by Addpharma, Inc. Primary endpoints: Area under the plasma concentration-time curve during dosing interval and Maximum concentration of drug in plasma. Planned start May 2026; status: not yet recruiting.
02
Drugs
telmisartan + amlodipine + chlorthalidone
03
Conditions
chronic liver disease (CLD)
Beyond the preview
Go deeper on NCT07618845.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07618845.